Literature DB >> 23609419

Acute myeloid leukemia associated with FGFR1 abnormalities.

Hyeyoung Lee1, Myungshin Kim, Jihyang Lim, Yonggoo Kim, Kyungja Han, Byung-Sik Cho, Hee-Je Kim.   

Abstract

Hematologic malignancies associated with FGFR1 abnormalities present in heterogeneous forms, including myeloproliferative neoplasm, acute myeloid leukemia (AML), T- or B-lineage lymphoblastic leukemia/lymphoma, and even mixed phenotype acute leukemia. In the present report, we describe three new cases of AML associated with FGFR1 abnormalities: AML with minimal differentiation with 45,XY,-7,t(8;13)(p11.2;q12), acute myelomonocytic leukemia with eosinophilia with 48,XY,t(8;9)(p11.2;q33),+19,+21, and AML with minimal differentiation with 46,XX,add(8)(p11.2). FGFR1 abnormalities were confirmed by fluorescence in situ hybridization. We reviewed the records of 19 patients reported from Asian countries, and found that approximately 40 % of cases manifested as acute leukemia associated with myeloid lineage, and 47 % were not accompanied with eosinophilia. These findings highlight the need for detection of FGFR1 abnormalities, not only in myeloproliferative disorder, but also in AML patients even without eosinophilia. The prognosis for this group of neoplasms is poor, and there is no recognized effective targeted treatment. Two patients, including our case, who received allogeneic hematopoietic stem cell transplantation (allo-HSCT) survived. Accumulation of long-term follow-up data can help determine the allo-HSCT protocol or the need for new therapeutic trials to improve the survival rate of patients with FGFR1 abnormalities.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23609419     DOI: 10.1007/s12185-013-1337-5

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  22 in total

1.  Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases.

Authors:  E Lierman; S Smits; J Cools; B Dewaele; M Debiec-Rychter; P Vandenberghe
Journal:  Leukemia       Date:  2012-01-17       Impact factor: 11.528

2.  The 8p11 myeloproliferative syndrome owing to rare FGFR1OP2-FGFR1 fusion.

Authors:  Masahiro Onozawa; Kazumasa Ohmura; Makoto Ibata; Junko Iwasaki; Kohei Okada; Ikumi Kasahara; Keisuke Yamaguchi; Kanako Kubota; Shinichi Fujisawa; Akio Shigematsu; Tomoyuki Endo; Takeshi Kondo; Satoshi Hashino; Junji Tanaka; Yoshihiro Matsuno; Masahiro Asaka; Masahiro Imamura
Journal:  Eur J Haematol       Date:  2011-02-18       Impact factor: 2.997

Review 3.  Rare translocations involving chromosome band 8p11 in myeloid neoplasms.

Authors:  Sang-Guk Lee; Tae Sung Park; Seung Tae Lee; Kyung-A Lee; Jaewoo Song; Juwon Kim; Borum Suh; Jong Rak Choi; Rojin Park
Journal:  Cancer Genet Cytogenet       Date:  2008-10-15

4.  A novel t(1;8)(q25;p11.2) translocation associated with 8p11 myeloproliferative syndrome.

Authors:  Chikamasa Yoshida; Makoto Takeuchi; Yoshito Sadahira
Journal:  Br J Haematol       Date:  2011-08-18       Impact factor: 6.998

5.  A chronic myelogenous leukemia-like myeloproliferative disorder accompanied by T-cell lymphoblastic lymphoma with chromosome translocation t(8;13)(p11;q12): a Japanese case.

Authors:  K Matsumoto; K Morita; S Takada; T Sakura; H Shiozaki; H Murakami; S Miyawaki
Journal:  Int J Hematol       Date:  1999-12       Impact factor: 2.490

6.  Clonal evolution of 8p11 stem cell syndrome in a 14-year-old Chinese boy: a review of literature of t(8;13) associated myeloproliferative diseases.

Authors:  Wai-Shan Wong; Kelvin Chi-Keung Cheng; Kin-Mang Lau; Natalie Pui-Ha Chan; Matthew Ming-Kong Shing; Suk-Hang Cheng; Ki-Wai Chik; Chi-Kong Li; Margaret Heung-Ling Ng
Journal:  Leuk Res       Date:  2006-06-13       Impact factor: 3.156

Review 7.  8p11 myeloproliferative syndrome: a review.

Authors:  Courtney C Jackson; L Jeffrey Medeiros; Roberto N Miranda
Journal:  Hum Pathol       Date:  2010-04       Impact factor: 3.466

8.  PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.

Authors:  Jing Chen; Daniel J Deangelo; Jeffery L Kutok; Ifor R Williams; Benjamin H Lee; Martha Wadleigh; Nicole Duclos; Sarah Cohen; Jennifer Adelsperger; Rachel Okabe; Allison Coburn; Ilene Galinsky; Brian Huntly; Pamela S Cohen; Thomas Meyer; Doriano Fabbro; Johannes Roesel; Lolita Banerji; James D Griffin; Sheng Xiao; Jonathan A Fletcher; Richard M Stone; D Gary Gilliland
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-24       Impact factor: 11.205

9.  A case of 8p11 myeloproliferative syndrome with BCR-FGFR1 gene fusion presenting with trilineage acute leukemia/lymphoma, successfully treated by cord blood transplantation.

Authors:  Satoshi Morishige; Eijiro Oku; Yuka Takata; Yoshizo Kimura; Fumiko Arakawa; Ritsuko Seki; Rie Imamura; Koichi Osaki; Michitoshi Hashiguchi; Kazuaki Yakushiji; Shinichi Mizuno; Koji Yoshimoto; Koji Nagafuji; Koichi Ohshima; Takashi Okamura
Journal:  Acta Haematol       Date:  2012-11-17       Impact factor: 2.195

10.  Chronic myelomonocytic leukaemia with t(8;9)(p11;q34) in childhood: an example of the 8p11 myeloproliferative disorder?

Authors:  H Nakayama; T Inamitsu; S Ohga; T Kai; M Suda; A Matsuzaki; K Ueda
Journal:  Br J Haematol       Date:  1996-03       Impact factor: 6.998

View more
  9 in total

1.  Chronic eosinophilic leukemia with a FIP1L1-PDGFRA rearrangement: Two case reports and a review of Korean cases.

Authors:  Sang-Yong Shin; Chul-Won Jung; Dong-Chull Choi; Byung-Jae Lee; Hee-Jin Kim; Sun-Hee Kim
Journal:  Blood Res       Date:  2015-03-24

2.  Re: Acute myeloid leukemia associated with FGFR1 abnormalities.

Authors:  John Jeongseok Yang; Seung Hwan Oh; Claus Meyer; Rolf Marschalek; Tae Sung Park
Journal:  Int J Hematol       Date:  2013-06-07       Impact factor: 2.490

3.  Reply to the letter by Yang et al. RE: acute myeloid leukemia associated with FGFR1 abnormalities.

Authors:  Yonggoo Kim; Hyeyoung Lee; Myungshin Kim
Journal:  Int J Hematol       Date:  2013-06-05       Impact factor: 2.490

4.  Aminoisoquinoline benzamides, FLT3 and Src-family kinase inhibitors, potently inhibit proliferation of acute myeloid leukemia cell lines.

Authors:  Elizabeth Larocque; N Naganna; Xiaochu Ma; Clement Opoku-Temeng; Brandon Carter-Cooper; Gaurav Chopra; Rena G Lapidus; Herman O Sintim
Journal:  Future Med Chem       Date:  2017-05-11       Impact factor: 3.808

5.  Two cases of concurrent development of essential thrombocythemia with chronic lymphocytic leukemia, one related to clonal B-cell lymphocytosis, tested by array comparative genomic hybridization.

Authors:  Hyunjung Kim; Woori Jang; Soyoung Shin; Joonhong Park; Myungshin Kim; Yonggoo Kim; Kyungja Han; Gun Dong Lee; Heusung Won; Young Jun Yang
Journal:  Int J Hematol       Date:  2014-12-10       Impact factor: 2.490

6.  Systemic mastocytosis with associated myeloproliferative neoplasm with t(8;19)(p12;q13.1) and abnormality of FGFR1: report of a unique case.

Authors:  Christina B Duckworth; Linsheng Zhang; Shiyong Li
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

7.  Loss of FGFR3 Delays Acute Myeloid Leukemogenesis by Programming Weakly Pathogenic CD117-Positive Leukemia Stem-Like Cells.

Authors:  Chen Guo; Qiuju Ran; Chun Sun; Tingting Zhou; Xi Yang; Jizhou Zhang; Shifeng Pang; Yechen Xiao
Journal:  Front Pharmacol       Date:  2021-01-29       Impact factor: 5.810

8.  Novel multiple tyrosine kinase inhibitor ponatinib inhibits bFGF-activated signaling in neuroblastoma cells and suppresses neuroblastoma growth in vivo.

Authors:  Haoyu Li; Yongfeng Wang; Zhenghu Chen; Jiaxiong Lu; Jessie Pan; Yang Yu; Yanling Zhao; Huiyuan Zhang; Ting Hu; Qing Liu; Jianhua Yang
Journal:  Oncotarget       Date:  2017-01-24

9.  Response of Myeloid Leukemia Cells to Luteolin is Modulated by Differentially Expressed Pituitary Tumor-Transforming Gene 1 (PTTG1) Oncoprotein.

Authors:  Pei-Yi Chen; Hsin-Jung Tien; Shih-Fen Chen; Chi-Ting Horng; Huei-Lin Tang; Hui-Ling Jung; Ming-Jiuan Wu; Jui-Hung Yen
Journal:  Int J Mol Sci       Date:  2018-04-12       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.